Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster session 13

1177P - Assessment of tumour burden reduction per photography vs magnetic resonance imaging in patients with locally advanced basal cell carcinoma receiving sonidegib 200 mg

Date

21 Oct 2023

Session

Poster session 13

Topics

Clinical Research

Tumour Site

Basal Cell and Squamous Cell Cancers of the Skin

Presenters

Ralf Gutzmer

Citation

Annals of Oncology (2023) 34 (suppl_2): S651-S700. 10.1016/S0923-7534(23)01941-5

Authors

R. Gutzmer1, F. Kiecker2, C. Loquai3, R. Dummer4, A. Hauschild5, N. Squittieri6, R. Arntz7, S. Martelli7, J. Dierlamm7, C. Robert8

Author affiliations

  • 1 Dermatology, Skin Cancer Center, Ruhr University Bochum Medizinische Universitätsklinik, 44892 - Bochum/DE
  • 2 Dermatology, Vivantes Klinikum Neukoelln, 12351 - Berlin/DE
  • 3 Dermatology, Universitätsmedizin der Johannes Gutenberg-Universität Mainz, 55118 - Mainz/DE
  • 4 Dermatology Department, Universitätsspital Zürich - Klinik für Dermatologie, 8091 - Zurich/CH
  • 5 Department Of Dermatology, UK-SH, Campus Kiel, 24105 - Kiel/DE
  • 6 Oncology And Dermatology, Sun Pharma, 08540 - Princeton/US
  • 7 Medical Affairs, Sun Pharmaceutical Industries (Europe) B.V., 2132 JH - Hoofddorp/NL
  • 8 Dermatology Department, Institut Gustave Roussy, 94805 - Villejuif, Cedex/FR

Resources

Login to get immediate access to this content.

If you do not have an ESMO account, please create one for free.

Abstract 1177P

Background

Sonidegib is a Hedgehog pathway inhibitor approved for the treatment of locally advanced basal cell carcinoma (laBCC) in the US, EU, Switzerland, and Australia, and metastatic BCC (mBCC) in Switzerland and Australia not amenable to curative surgery or radiotherapy. This analysis compared tumour burden reduction using photography or magnetic resonance imaging (MRI) in patients with laBCC that had a time to first tumour response (TFTR) within 6 months of starting treatment.

Methods

The double-blind, multicentre, phase II BOLT study assessed the efficacy and safety of sonidegib 200 mg with laBCC. Tumour burden reduction was assessed using both colour photography and MRI by central review. Tumour response was defined as a >10 mm unidimensional decrease in tumour size. Safety assessments included adverse event (AE) monitoring.

Results

Overall, among 66 patients with laBCC receiving sonidegib 200 mg, TFTR <3 months was achieved by 31 patients per photography and 11 patients per MRI assessment; TFTR from 3 to <6 months was achieved by 8 patients per photography and 12 per MRI. For patients with a TFTR of <3 months, the median (minimum, maximum) percent change from baseline in tumour size was −18.5 (−100.0, 35.9) vs −23.8 (−100.0, −11.9) at 9 weeks, −33.4 (−100.0, 38.5) vs −54.0 (−100.0, −27.1) at 25 weeks, −30.7 (−100.0, 12.0) vs −82.1 (−100.0, −52.9) at 41 weeks, and −29.0 (−100.0, 57.8) vs −82.1 (−100.0, −58.8) at 61 weeks per photography vs MRI, respectively. For patients with a TFTR from 3 to <6 months, the median (minimum, maximum) percent change from baseline in tumour size was not available at 9 weeks, −16.0 (−100.0, 18.1) vs −37.0 (−77.3, −12.5) at 25 weeks, −32.9 (−54.7, 22.3) vs −79.2 (−100.0, −41.5) at 41 weeks, and −35.1 (−46.8, −23.4) vs −77.3 (−100.0, −31.6) at 61 weeks per photography vs MRI, respectively. Sonidegib was well tolerated, and most AEs were Grade 1/2 in severity.

Conclusions

In patients with a TFTR within 6 months of starting treatment with sonidegib, an overall greater reduction in tumour size was reported per MRI assessment vs photography, with photography underestimating the extent of tumour response.

Clinical trial identification

NCT01327053.

Editorial acknowledgement

Writing and editorial support were provided by Duncan McCloskey, PhD, of AlphaBioCom, a Red Nucleus company, and funded by Sun Pharma.

Legal entity responsible for the study

Sun Pharma.

Funding

Sun Pharma.

Disclosure

R. Gutzmer: Non-Financial Interests, Personal, Speaker, Consultant, Advisor: Almirall, Amgen, Bristol Myers Squibb, Immunocore, Merck Serono, Merck Sharp & Dohme, Novartis, Pfizer, Pierre Fabre, Roche, Sanofi Genzyme, Sun Pharmaceutical Industries, Inc., 4SC, Bayer; Non-Financial Interests, Personal, Research Funding: Amgen, Johnson & Johnson, Merck Serono, Novartis; Financial Interests, Advisory Board: Sun Pharmaceutical Industries, Inc. F. Kiecker: Financial Interests, Personal, Research Grant: Amgen, Bristol Myers Squibb, Merck Sharp & Dohme, Novartis, Pierre Fabre, Roche, Sanofi. C. Loquai: Non-Financial Interests, Personal, Advisory Board: Bristol Myers Squibb, Roche, Novartis, Merck Sharp & Dohme. R. Dummer: Non-Financial Interests, Personal, Advisory Board: Amgen, Bristol Myers Squibb, CatalYm, Merck Sharp & Dohme, Novartis, Pierre Fabre, Roche, Sanofi, Second Genome, Sun Pharmaceutical Industries, Inc., Takeda. A. Hauschild: Non-Financial Interests, Personal, Speaker, Consultant, Advisor: Roche, Novartis, Amgen, Celgene, GSK, MedImmune, MelaSciences, Merck Serono, OncoSec, Eisai; Non-Financial Interests, Personal, Research Funding: Roche, Novartis, Amgen, Celgene, GSK, MedImmune, MelaSciences, Merck Serono, OncoSec, Eisai. N. Squittieri, R. Arntz, S. Martelli, J. Dierlamm: Financial Interests, Personal, Full or part-time Employment: Sun Pharmaceutical Industries Inc. C. Robert: Non-Financial Interests, Personal, Speaker, Consultant, Advisor: Amgen, Array BioPharma, Bristol Myers Squibb, Merck, Merck Serono, Novartis, Pierre Fabre, Roche.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.